Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-Up of the MARIPOSA Study : Episode 2

Amivantamab Plus Lazertinib Clinical Efficacy

October 8, 2024

By Joshua K. Sabari, MD
Sandip Patel, MD

Opinion

Video

Panelists discuss how the MARIPOSA study shows more patients in the amivantamab-lazertinib arm continued treatment compared to osimertinib, and many who progressed initiated subsequent therapy, primarily with carboplatin-pemetrexed.

EP: 1.Overview of MARIPOSA Study

Now Viewing

EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy

EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib

EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

EP: 5.Putting Amivantamab Plus Lazertinib Into Practice

EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!